U.S. Health and Human Services Secretary Robert F. Kennedy Jr. (RFK Jr.) is preparing to release a report that will link he use of Tylenol during pregnancy, claiming a potential link between the popular pain reliever and autism in children.
The report, first previewed by The Wall Street Journal, has already sent shockwaves through the pharmaceutical and medical communities, and it caused shares of Tylenol maker Kenvue to plunge 14 percent on Friday.
According to individuals familiar with the matter, Kennedy’s forthcoming announcement will suggest that pregnant women who take acetaminophen — the active ingredient in Tylenol — could be increasing the risk of autism in their children.
The report is also expected to highlight research indicating that low folate levels during pregnancy, combined with acetaminophen exposure, may contribute to developmental disorders. In addition, Kennedy plans to argue that a form of folate known as folinic acid may provide treatment options for people already diagnosed with autism.
The Department of Health and Human Services has not yet confirmed or commented on the report. But if released as expected, it will represent one of the most controversial public health statements in years, especially given that acetaminophen is widely